Exclusive Summary

• **Revolutionary Dosage Form**: Combines the long-acting benefit of injections (once-weekly) with the convenience of oral administration (needle-free), overcoming the daily dosing and fasting strictures of oral tablets (Rybelsus).
• **Enhanced Bioavailability & Safety**: Bypasses hepatic first-pass metabolism and GI enzymatic degradation via buccal absorption, significantly reducing GI side effects (nausea/vomiting) and eliminating food-effect interactions.
• **Innovative Platform Technology**: Utilizes 3D-printed suction patches (adhesive-free) that mechanically stretch mucosal channels for delivery, ensuring stability against saliva while minimizing irritation compared to chemical adhesives.
• **Strong Preclinical POC**: Beagle dog PK data demonstrates a half-life supporting a once-weekly dosing regimen, validating the feasibility of this non-invasive delivery system for further status development.

Asset Materials

Contact Us for Full Materials